Lupin recalls 42 lots of antibiotic after contaminate found in vials

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/westend61)
(Image: Getty/westend61)

Related tags: Recall, Fda, Injection, Antibiotics, Inspection

Lupin Pharmaceuticals voluntarily recalling lots of Ceftriaxone for Injection after rubber flecks were found in vials.

The recall comes after Ceftriaxone for injection products have been found to contain visual grey particulate matter in reconstituted vials.

The five lots recalled contained Ceftriaxone for Injection, 250mg, 10 lots of Ceftriaxone for Injection, 500mg, 24 lots of Ceftriaxone for Injection, 1g, and three lots of Ceftriaxone for Injection, 2g.

Lupin stated that improper piercing and use of a needle greater than 21 gauge while reconstituting the vial can push rubber flecks into the solution.

No grey flecks were seen prior to the constitution of the vials. The issue was identified after standard visual inspection prior to patient administration.

The product containing rubber particulate matter could cause vein irritation or pulmonary embolic events potentially resulting in permanent impairment of bodily function if injected with the contaminant.

As ceftriaxone can be administered intramuscularly, the use of the product with its contaminant can cause local muscle inflammation and abscesses.

Ceftriaxone is a sterile, semi-synthetic, broad-spectrum cephalosporin antibiotic used to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone sodium, and other antibacterial drugs.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars